Millennium Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $25.5M | Sell |
419,900
-524,600
| -56% | -$30.6M | 0.01% | 1346 |
|
|
2025
Q4 | $50.9M | Sell |
944,500
-520,500
| -36% | -$25M | 0.02% | 809 |
|
|
2025
Q3 | $66.1M | Buy |
1,465,000
+776,300
| +113% | +$36.3M | 0.03% | 679 |
|
|
2025
Q2 | $31.9M | Sell |
688,700
-131,600
| -16% | -$6.46M | 0.02% | 1140 |
|
|
2025
Q1 | $50M | Buy |
820,300
+70,200
| +9% | +$4.09M | 0.03% | 767 |
|
|
2024
Q4 | $42.4M | Buy |
750,100
+291,700
| +64% | +$16.3M | 0.02% | 894 |
|
|
2024
Q3 | $23.7M | Buy |
458,400
+225,900
| +97% | +$10.6M | 0.01% | 1393 |
|
|
2024
Q2 | $9.66M | Sell |
232,500
-137,300
| -37% | -$6.14M | ﹤0.01% | 2107 |
|
|
2024
Q1 | $20.1M | Buy |
369,800
+87,300
| +31% | +$4.45M | 0.01% | 1553 |
|
|
2023
Q4 | $14.5M | Sell |
282,500
-350,300
| -55% | -$18.4M | 0.01% | 1835 |
|
|
2023
Q3 | $36.7M | Buy |
632,800
+30,600
| +5% | +$1.87M | 0.02% | 920 |
|
|
2023
Q2 | $38.5M | Buy |
602,200
+14,000
| +2% | +$939K | 0.02% | 911 |
|
|
2023
Q1 | $40.8M | Sell |
588,200
-352,300
| -37% | -$24.8M | 0.02% | 825 |
|
|
2022
Q4 | $67.7M | Buy |
940,500
+89,500
| +11% | +$6.75M | 0.04% | 567 |
|
|
2022
Q3 | $60.5M | Sell |
851,000
-530,700
| -38% | -$38.5M | 0.04% | 571 |
|
|
2022
Q2 | $106M | Sell |
1,381,700
-689,100
| -33% | -$52.5M | 0.07% | 278 |
|
|
2022
Q1 | $151M | Buy |
2,070,800
+92,500
| +5% | +$6.21M | 0.08% | 184 |
|
|
2021
Q4 | $123M | Buy |
1,978,300
+631,400
| +47% | +$37M | 0.06% | 274 |
|
|
2021
Q3 | $79.7M | Sell |
1,346,900
-206,700
| -13% | -$13.6M | 0.05% | 403 |
|
|
2021
Q2 | $104M | Sell |
1,553,600
-746,700
| -32% | -$48.7M | 0.06% | 281 |
|
|
2021
Q1 | $145M | Buy |
2,300,300
+1,611,900
| +234% | +$100M | 0.1% | 141 |
|
|
2020
Q4 | $42.7M | Sell |
688,400
-1,019,400
| -60% | -$62.7M | 0.03% | 542 |
|
|
2020
Q3 | $103K | Sell |
1,707,800
-780,800
| -31% | -$47M | 0.13% | 122 |
|
|
2020
Q2 | $146M | Buy |
2,488,600
+718,100
| +41% | +$43M | 0.2% | 59 |
|
|
2020
Q1 | $98.7M | Sell |
1,770,500
-334,100
| -16% | -$20.4M | 0.22% | 63 |
|
|
2019
Q4 | $135M | Buy |
2,104,600
+1,142,300
| +119% | +$65.4M | 0.17% | 93 |
|
|
2019
Q3 | $48.8M | Buy |
962,300
+932,300
| +3,108% | +$43.8M | 0.08% | 314 |
|
|
2019
Q2 | $1.36M | Sell |
30,000
-378,500
| -93% | -$17.6M | ﹤0.01% | 2627 |
|
|
2019
Q1 | $19.5M | Buy |
+408,500
| New | +$20.3M | 0.03% | 811 |
|
|
2018
Q2 | – | Sell |
-50,000
| Closed | -$3.16M | – | 3798 |
|
|
2018
Q1 | $3.16M | Sell |
50,000
-67,400
| -57% | -$4.34M | ﹤0.01% | 2068 |
|
|
2017
Q4 | $7.19M | Sell |
117,400
-382,600
| -77% | -$23.9M | 0.01% | 1533 |
|
|
2017
Q3 | $31.9M | Buy |
+500,000
| New | +$29.2M | 0.05% | 537 |
|
|
2017
Q2 | – | Sell |
-675,000
| Closed | -$36.7M | – | 3469 |
|
|
2017
Q1 | $36.7M | Buy |
+675,000
| New | +$37M | 0.07% | 411 |
|
|
2016
Q4 | – | Sell |
-125,000
| Closed | -$6.74M | – | 3343 |
|
|
2016
Q3 | $6.74M | Buy |
+125,000
| New | +$8.03M | 0.01% | 1155 |
|
|
2015
Q1 | – | Sell |
-11,100
| Closed | -$655K | – | 3586 |
|
|
2014
Q4 | $655K | Sell |
11,100
-94,900
| -90% | -$5.35M | ﹤0.01% | 2806 |
|
|
2014
Q3 | $5.42M | Buy |
106,000
+5,300
| +5% | +$265K | 0.01% | 1246 |
|
|
2014
Q2 | $4.88M | Buy |
+100,700
| New | +$4.96M | 0.01% | 1236 |
|
|
2014
Q1 | – | Sell |
-105,300
| Closed | -$5.6M | – | 3455 |
|
|
2013
Q4 | $5.6M | Buy |
105,300
+15,700
| +18% | +$800K | 0.02% | 1080 |
|
|
2013
Q3 | $4.15M | Buy |
+89,600
| New | +$3.93M | 0.01% | 1226 |
|
Other funds holding BMY
VCM
VPM
Millennium Management's BMY Position: Q1 2026 in Review
Millennium Management increased its Bristol-Myers Squibb (BMY) stake by 780% in Q1 2026, buying an estimated $338M and bringing the position to 6,545,442 shares worth $397M. The position accounts for 0.17% of the portfolio, ranked #93.
Millennium Management first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $480M in Q4 2024. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Millennium Management held 6,545,442 shares of Bristol-Myers Squibb worth $397M as of Q1 2026.
- Millennium Management bought 5,801,783 Bristol-Myers Squibb shares in Q1 2026, an estimated $338M.
- Bristol-Myers Squibb made up 0.17% of Millennium Management's portfolio in Q1 2026, its #93 holding.
- Millennium Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
- Millennium Management's Bristol-Myers Squibb position peaked at $480M in Q4 2024.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.